

## **BIOTECHNOLOGICAL SECTOR**

### **Vaccine production plant**

Building a closed cycle plant to obtain bacterial vaccines from pathogenic micro-organisms, enteric vaccines, and vaccines based on external membrane protein, attenuated and conjugate vaccines.

This plant will be designed under Good Production Practices regulations. Some of the vaccines to be produced: cholera, meningococcal, meningococcal conjugate and salmonella variants, etc.) This project must be conceived as a vaccine production complex with several production lines of pharmaceutical ingredients and finished products. Production is fundamentally for export.

Investment Type: **International Economic Association**

Estimated Investment: **165 million USD**

### **Homeopathic products production plant**

Building a production complex for homeopathic compounds in liquid presentations of the different lines of Vacunas Finlay S.A. products (homeopathic complexes and nosodes). The lines will cover all existing branches (PrevengHo, AliviHo, TratHo, EstimulHo) to be produced on an industrial basis for domestic consumption and for exportation agreements. A plant should also be built to have areas for formulation, dynamo dilution, filling and final bottling. It will also have warehouses for initial raw materials, inflammable substances (alcohol) and finished products as well as areas for the services for generating purified water and pure steam.

Investment Type: **International Economic Association**

Estimated Investment: **15.3 million USD**

### **Plant for producing natural products based on powders and fluid extracts**

Production and commercialization of natural products based on powders and fluid extracts from medicinal plants destined for the domestic market and export. The objective of proposed investment project is to create a production infrastructure for processing medicinal plants and obtaining medicines from natural products based on powders, capsules and fluid extracts. It also includes the machinery and infrastructure to process drying and improvements in the field.

Investment Type: **International Economic Association**

Estimated Investment: **35 million USD**

### **Plant for producing monoclonal antibodies**

Building an industrial biotechnological facility to produce monoclonal antibodies for therapeutic use in cancer and other chronic diseases (capacity of 100 Kg per year), from the active pharmaceutical ingredient right up to the final product. Including warehouses, offices and technological services. Production is basically for export.

Investment Type: **International Economic Association**

Estimated Investment: **90 million USD**

### **Plant for oral solid medicines (tablets and capsules)**

Building a plant to manufacture generic medicines in solid oral forms. We plan a production plant having a nominal capacity of 4500 million tablets and 500 million capsules per year. Production is fundamentally for export.

Investment Type: **International Economic Association**

Estimated Investment: **100 million USD**

### **Plant for producing antiretroviral medicines**

Building a plant to produce generic antiretroviral medicines in solid oral form, with a nominal capacity of 300 million units per year. Production is fundamentally for export.

Investment Type: **International Economic Association**

Estimated Investment: **25 million USD**

### **Plant for contraceptive products**

Designing and building a plant to manufacture oral and hormone contraceptive pills and their principal active ingredients (hormones and antihormones), classified to levels of contention 5 (OEL5) including activities "in process" and control testing of production underway. The new plant will fulfill the following process requirements:

- Capacity : 500,000,000 pills per year
- Forms : 7 different forms

Production is fundamentally for export.

Investment Type: **International Economic Association**

Estimated Investment: **25 million USD**

### **Blood-based products plant**

Building a production plant to process 100,000 liters of plasma a year, with yields of 18 gr to 23 gr of protein/liter of plasma. Incorporation via transference technology of producing Blood- Clotting Factor VIII and Factor IX. Production is fundamentally for export.

Investment Type: **International Economic Association**

Estimated Investment: **160 million USD**

### **Plant to produce injectable medicines**

Building a production plant for injectable liquids, complying with Drug Industry Good Manufacturing Practices, of the following:

- Injectable ampoules
- Injectable liquid bulbs
- Pre-filled syringes

Installation plans are for a production capacity of 20 million ampoules per year, 20 million vials with liquid and lyophilized products and 10 million pre-filled syringes per year for an assortment including sterilized products obtained by aseptic processing and terminal sterilization. Production is basically for exportation.

Investment Type: **International Economic Association**

Estimated Investment: **160 million USD**

### **Plant to produce measured dosage sprays**

Building a pharmaceutical plant to manufacture dose-inhalers, basically bronchodilator products to treat asthma, allergic respiratory diseases and chronic obstructive pulmonary diseases (COPD). Technological transfer of nationally produced products and the introduction of new products for COPDs. Production is destined basically for exportation.

Investment Type: **International Economic Association**

Estimated Investment: **55 million USD**

### **Plant to produce solid oral medicines (tablets, caplets and capsules)**

Building a plant to produce solid forms from natural products. For the Cuban and Latin American markets

Investment Type: **International Economic Association**

Estimated Investment: **40 million USD**

### **Plant to produce cephalosporins and carbapenemas (injectable)**

Building a plant to produce cephalosporins and carbapenemas (injectable) with a capacity to obtain up to 21 million ampoules per year. Production will be destined to satisfy domestic demands and the rest will be for exportation.

Investment Type: **International Economic Association**

Estimated Investment: **60 million USD**

### **Plant to produce oral penicillin-based antibiotics**

Building a plant to produce and sell oral penicillin-based antibiotics for oral suspensions with and without beta-lactamase inhibitors, with a capacity in the first stage of 500 million capsules and 20 million bottles for suspensions, produced on the basis of imported active principles. Production is for exportation and domestic sales to satisfy the demands for these medicines

Investment Type: **International Economic Association**

Estimated Investment: **30 million USD**